Lupin Share price

Q: How to buy Lupin Share at Choice?

To buy Lupin stocks , log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Lupin, choose your preferred order type, and place the trade.

LUPIN

Healthcare Large Cap

2281.8

2.70 (-0.12%)

NSE

BSE

Last updated on 22 May, 2026 | 15:56 IST

BUYSELL

Today's High

2304.50

Today's Low

2270.00

52 Week Low

1836.80

52 Week High

2494.00

Free Demat with Zero AMC*

Lupin Chart

ChartIQ

TradingView

Lupin Share Key Metrics

Volume

12.25 L

Market Cap

104288.12 CR

LTQ@LTP

1@2281.80

ATP

2284.33

Var Margin

12.92 %

Circuit Range

2056.1-2512.9

Delivery %

56.25 %

Value

279.88 CR

ASM/GSM

No

Market Lot

1

Summary

Lupin share price is ₹2281.8 as of 23 May, 2026. The stock Lupin intraday movement has stayed between ₹2270.00 and ₹2304.50, while on a 52-week basis,Lupin price 52 week high is ₹2494.00 & its 52 week low is ₹1836.80.

In terms of trading activity, Lupin has recorded a volume of 1225221 shares, The Lupin has a market cap of ₹457043219 CR. The stock’s Average Traded Price (ATP) stands at ₹2284.33, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 1 @ ₹2281.80.

Lupin operates within a circuit range of ₹2056.10 – ₹2512.90, with a Value of ₹279.88 CR. The Delivery Percentage for the day is 56.25%. Additionally, Lupin currently falls under the No framework, and trades with a market lot size of 1.

Lupin Fundamentals

P/E Ratio

19.54

P/B Ratio

4.64

Div. Yield

0.79

Sector P/E

70.19

Sector P/B

3.46

Sec. Div. Yield

0.55

Lupin Resistance and Support

Pivot 2286.13

Resistance

First Resistance

2302.66

Second Resistance

2320.83

Third Resistance

2337.36

Support

First Support

2267.96

Second Support

2251.43

Third Support

2233.26

Lupin Futures & Options

Lupin Ltd Share Price

2281.8

-2.7 (-0.12%)

Lupin Option Chain

View Price, OI, Greeks & More...

View All

26MAY26

2271.80

5.00 (0.22%)

30JUN26

2263.40

-0.70 (0.03%)

28JUL26

2259.00

-8.20 (0.36%)

LUPIN|26MAY26 CE 2280.00

9.20 -4.8 (-34.29%)

LUPIN|26MAY26 PE 2300.00

34.2 -7.35 (-17.69%)

Lupin Shareholding Pattern

2016-17
2018-19
2019-20
2020-21
2021-22
2022-23
2023-24
2024-25
2025-26
2026-27

Total Promoters

Segment

Percent

Total Promoters

46.86%

Mutual Fund

16.93%

Insurance

6.12%

Foreign Institutional Investors

21.7%

Domestic Institutional Investors

2.28%

Retail

6.11%

Others

0%

Total Promoters

MAR '26

46.86%

Lupin Corporate Actions

Date	Agenda
2026-05-07	Audited Results & Final Dividend
2026-02-12	Quarterly Results
2025-11-06	Quarterly Results & Others
2025-08-05	Quarterly Results & Others
2025-05-14	Audited Results & Final Dividend
2025-02-11	Quarterly Results & Others

Lupin News

Lupin gets approval to launch flu medicine in China, enters Chinese market for first time

Lupin Limited has entered into a license and supply agreement with China's Sino Universal Pharmaceuticals (SUP) to commercialize Tiotropium Dry Powder Inhaler (DPI) in the Chinese market. This move expands Lupin's product offerings and strengthens its presence in the key therapeutic area of respiratory diseases in China.

May 22 2026 16:05:00

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin received China's NMPA approval for Oseltamivir Phosphate Oral Suspension, marking its debut in the Chinese market. This expands Lupin's global footprint for high-quality, affordable medicines, especially for pediatric use, in partnership with Yabao Pharmaceuticals.

May 22 2026 15:05:00

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin Limited has been featured for the first time in the Dow Jones Best-in-Class Indices (DJBIC) for 2026, covering both World and Emerging Markets indices. This inclusion highlights the company's strong commitment to sustainable and ethical business practices, reinforcing its credibility with global investors.

May 19 2026 11:05:00

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin secured tentative approval from the U.S. FDA for Revefenacin Inhalation Solution, 175 mcg/3 mL Unit-Dose Vials. This generic drug is indicated for Chronic Obstructive Pulmonary Disease (COPD), targeting a market with $260.7 million in annual sales.

May 18 2026 21:05:00

Lupin Limited

Lupin Limited received tentative approval from the U.S. FDA for its Revefenacin Inhalation Solution (175 mcg/3 mL). This drug is bioequivalent to Mylan's Yupelri® and is indicated for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD).

May 18 2026 21:05:00

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin received U.S. FDA approval for its Famotidine Injection, USP. This approval allows the company to commercialize the product in the United States, targeting an estimated $8.7 million in annual sales.

May 13 2026 18:05:00

Lupin Limited

Lupin Limited has received U.S. FDA approval for its Famotidine Injection, USP. This approval opens the U.S. market for the product, which had estimated annual sales of USD 8.7 million as of March 2026. The drug will be manufactured at Lupin's Nagpur facility.

May 13 2026 18:05:00

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Lupin released the audio recording of its Q4 FY26 earnings call. The recording, from the call held on May 08, 2026, is available on the company's website for investor access.

May 08 2026 21:05:00

Lupin shares may react to record US sales in Q4, strong operating performance

Lupin reported a strong financial performance for Q4 FY2026, with consolidated net profit surging 87.7% to ₹1,468.7 crore and revenue increasing 32.9% to ₹7,391.9 crore. This growth was primarily driven by robust sales in the US market and significant expansion in EBITDA margins, which reached 33.6%. The company's board also recommended its highest-ever dividend of ₹18 per equity share for FY2026.

May 08 2026 08:05:00

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin announced strong Q4 FY26 and full-year results, with Q4 net profit increasing 87.7% YoY to Rs.1,468.7 cr and sales growing 32.9% to Rs.7,391.9 cr. The full-year net profit rose 62.0% to Rs.5,355.5 cr, and the Board recommended a 900% dividend.

May 07 2026 21:05:00

NSE : 10440

BSE : 500257

ISIN : INE326A01037

Lupin Management

Name	Position
Manju D Gupta	Chairperson
Nilesh Gupta	Managing Director

Lupin Similar Stocks

Cipla Ltd.

1399.20

-2.70 (0.19%)

Dr. Reddy's Laboratories Ltd.

1307.20

-11.30 (0.86%)

Mankind Pharma Ltd.

2479.40

-34.70 (1.38%)

Max Healthcare Institute Ltd.

1023.25

-67.85 (6.22%)

Zydus Lifesciences Ltd.

1038.95

2.50 (0.24%)

Aurobindo Pharma Ltd.

1463.50

-83.20 (5.38%)

Lenskart Solutions Ltd.

513.95

15.45 (3.10%)

Fortis Healthcare Ltd.

960.40

-6.90 (0.71%)

Laurus Labs Ltd.

1343.50

-7.50 (0.56%)

Biocon Ltd.

430.25

-0.60 (0.14%)

Lupin FAQs

The Buying Price of Lupin share is 2281.8 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Lupin stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Lupin, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Lupin shares is 19.54. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Lupin shares is 4.64. Useful to assess the stock's value relative to its book value.

To assess Lupin’s valuation compare Sector P/E, P/B which are 70.19 & 3.46 with sector averages, along with growth rates and financial metrics.

The Market Cap of Lupin is 104288.12 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Lupin share price is 2494.00 & 1836.80. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Lupin belongs to the Healthcare sector.